Publikationen in Zusammenarbeit mit Forschern von Gustave Roussy Cancer Campus (1)

2022

  1. IBCL-271 Primary Efficacy and Safety Analysis of a Global Phase II Study of Zandelisib Administered by Intermittent Dosing (ID) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): The TIDAL Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S387-S388